title: Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.
abstract: OBJECTIVE
  To explore the association between rs3758539G-803A and rs10882283T-179G polymorphism of retinol binding protein 4 (RBP4) and rosiglitazone response in Chinese type 2 diabetes mellitus (T2DM) patients.
  
  
  METHODS
  A total of 472 Chinese T2DM patients and 198 healthy subjects were enrolled to identify G-803A and T-179G genotypes using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Forty-two T2DM patients with different G-803A or T-179G genotypes were selected to undergo a 12-week rosiglitazone treatment (4 mg/d). Serum fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting serum insulin (FINS), glycated hemoglobin (HbAlc), postprandial serum insulin (PINS), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c) were determined before and after the rosiglitazone treatment.
  
  
  RESULTS
  T2DM patients with RBP4 G-803A GG genotype showed lower TG and LDL-c concentrations compared with that in the GA+AA genotype subjects. T2DM patients with RBP4 T-179G TT genotype showed lower waist-to-hip ratio (WHR), FPG and FINS values compared with that in the TG+GG genotype individuals. Patients with GG genotype of RBP4 G-803A had an enhanced rosiglitazone efficacy on FPG and FINS compared with that in the GA+AA genotype group. Patients with RBP4 T-179G TG+GG genotype showed an enhanced rosiglitazone efficacy on HbAlc level compared with that in the TT genotype group.
  
  
  CONCLUSIONS
  RBP4 G-803A and T-179G polymorphism might be associated with the development of T2DM and affect the therapeutic efficacy of rosignitazone in Chinese T2DM patients.
authors.affiliation: Central South University, Changsha, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Qiong
authors.initials: Q
authors.lastname: Huang
authors.forename: Xingping
authors.initials: X
authors.lastname: Dai
authors.forename: Jiye
authors.initials: J
authors.lastname: Yin
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Honghao
authors.initials: H
authors.lastname: Zhou
authors.forename: Zhicheng
authors.initials: Z
authors.lastname: Gong
authors.forename: Zhaoqian
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D054839:Retinol-Binding Proteins, Plasma / Q000235:genetics*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D045162:Thiazolidinediones; D000077154:Rosiglitazone